Search Saint Luke's

Dr. Anezi Uzendu and colleagues examined whether EMS agencies that work in Black and Hispanic communities have lower survival rates for OHCA than agencies in white communities.

Dr. Suzanne Arnold and colleagues performed an in-depth analysis of the health status of patients enrolled in the TRISCEND II pivotal trial.

Saint Luke’s Hospital Medical/Surgical/Trauma Intensive Care Unit (MSTICU) Advanced Pharmacy Practice Experience (APPE) Rotation is a month-long clinical rotation designed to expand on basic clinical knowledge and abilities gained on previous rotations, and to enhance the student’s critical-thinking skills. 

Medicare is health insurance for people 65 or older. Medicare's open enrollment period runs from Oct. 15 through Dec. 7 every year. During this time, you can review Medicare coverage options and make changes to your plan. Below are resources to help you understand your options, including a list of plans accepted by Saint Luke’s providers. 

The Medication Safety rotation is a one-month rotation designed to provide students with a broad perspective of medication safety topics and activities in a health-system. It will build on the student’s basic clinical knowledge and understanding of pharmacy operations and will enhance the student’s critical thinking skills.

Tricuspid transcatheter edge-to-edge repair performed better than anticipated in patients expected to have only a modest benefit due to more complex anatomy, the TRILUMINATE trial showed.

Since the first SGLT2 inhibitor drug was approved in 2013, the medications have gone from targeting glucose-lowering to also providing cardiac protection and heart benefits.

Medscape talked to Susie Krug about how virtual nursing is transforming the way Saint Luke's provides care.

May marks Mental Health Awareness Month, a time to come together to raise awareness, reduce stigma, and promote understanding about mental health.

Breast Cancer 
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer